iBio, Inc. (IBIO)
| Market Cap | 16.41M |
| Revenue (ttm) | 400,000 |
| Net Income (ttm) | -18.38M |
| Shares Out | 19.65M |
| EPS (ttm) | -1.75 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 367,999 |
| Open | 0.8052 |
| Previous Close | 0.8113 |
| Day's Range | 0.7999 - 0.8395 |
| 52-Week Range | 0.5562 - 6.8910 |
| Beta | 0.86 |
| Analysts | Strong Buy |
| Price Target | 5.50 (+558.68%) |
| Earnings Date | Sep 5, 2025 |
About IBIO
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its produc... [Read more]
Financial Performance
In 2025, iBio, Inc.'s revenue was $400,000, an increase of 77.78% compared to the previous year's $225,000. Losses were -$18.38 million, -26.22% less than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for IBIO stock is "Strong Buy." The 12-month stock price target is $5.5, which is an increase of 558.68% from the latest price.
News
iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced its financial results for the fiscal year ended June 30,...
iBio Announces Closing of $50 Million Public Offering
Total gross proceeds of $100 million if all Series G warrants and Series H warrants are exercised for cash Financing was led by Balyasny Asset Management and included participation from Cormorant Asse...
iBio Announces Pricing of $50 Million Public Offering
SAN DIEGO, Aug. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced the pricing of an underwritten public offering (the “off...
iBio Announces Proposed Public Offering
SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced it has commenced an underwritten public offering (the “o...
iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results
Lead amylin receptor agonist engineered antibody significantly reduced acute food intake in a mouse model of obesity, comparable to the efficacy of a leading amylin peptide agonist
iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call
Review of promising Myostatin and Activin E antibody data iBio to announce 3 rd target in Astral Bio Collaboration Conference call Tuesday, June 24 at 8:30 a.m. ET SAN DIEGO, June 23, 2025 (GLOBE NEWS...
iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment
iBio nominates IBIO-610 as development candidate for its first-in-class Activin E antibody New study aims to evaluate the half-life of IBIO-610 in obese, elderly non-human primates (NHP) and assess ea...
iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model
SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced new promising preclinical data for its first-in-class Act...
iBio Reports Fiscal Third Quarter 2025 Financial Results
SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq:IBIO), today reported financial results for the third quarter ended March 31, 2025, and provided a corporate update on its progress.
iBio Raises $6.2 Million Through Warrant Inducement Transaction
SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody therapies, announces today announced that it has entered...
iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio
In-Licensing of novel activin E antibody underscores iBio's commitment to delivering meaningful benefits to patients living with obesity and cardiometabolic diseases In-Licensing of novel activin E an...
iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline
Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 days
iBio to Begin Trading on the Nasdaq Stock Exchange
SAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody therapies, today announced that iBio's common stock has been approved for listing on ...
iBio Reports Fiscal Second Quarter 2025 Financial Results
SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), today reported financial results for the second quarter ended Dec. 31, 2024, and provided a corporate update on its progress.
iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio
Building on the success of the anti-Myostatin program, iBio Launches New Program Featuring Myostatin + Activin A Bispecific Antibody Designed to Promote Weight Loss, Prevent Muscle Loss and Weight Reg...
iBio Reports Fiscal First Quarter 2025 Financial Results
Advanced myostatin program with dosing underway in non-human primate study Advanced myostatin program with dosing underway in non-human primate study
iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
SAN DIEGO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced its financial results for the fiscal year ended Jun...
iBio to Participate in Upcoming Investor Conferences
SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today that CEO and Chief Scientific Officer, Martin Brenn...
iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development
Life sciences industry veteran to lead strategic alliances for iBio's machine learning platform for antibody discovery and pipeline of cardiometabolic targets Life sciences industry veteran to lead st...
iBio Closes Sale of Manufacturing Facility in Texas
– The sale of the facility eliminates $13.2M of secured debt – – Completes iBio's transition to an AI and precision biologics innovation company - SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- iBio, ...
iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
BRYAN, Texas and SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today reported financial r...
iBio stock nearly tripled on Wednesday: here's why
Shares of iBio Inc (NYSEAMERICAN: IBIO) close to tripled on Wednesday after the biotechnology company announced a collaboration with AstralBio Inc.
iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases
– Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments –
iBio Announces $15.0 Million Private Placement
– Purchase price of $2.85 represents a premium of 148+% to last close – BRYAN, Texas and SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven i...
iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka
– Deal includes $1 million upfront and potential future milestone payments – – iBio's proprietary therapeutic pipeline will now be comprised entirely of promising immuno-oncology candidates – BRYAN, T...